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Abstract
Peptic ulcer disease (PUD) is one of the commonest diseases seen throughout
the world. There are various risk factors for the development of peptic ulcer disease,
but the most important ones are Helicobacter pylori infection and nonsteroidal anti-
inflammatory drugs (NSAIDs). Patients generally present with dyspepsia or peptic
ulcer bleeding. Acid suppressant therapy, H. pylori eradication, and avoidance of
nonsteroidal anti-inflammatory drugs are the cornerstones of treatment of peptic
ulcer disease. Peptic ulcer bleeding could be life-threatening. It is managed by
appropriate supportive care, intravenous proton pump inhibitor therapy, and
endoscopic hemostasis. Transarterial embolization (TAE) and surgery are rarely
required if endoscopic therapy fails.
Keywords: peptic ulcer disease, dyspepsia, H. pylori infection,
peptic ulcer bleeding, endoscopic treatment of peptic ulcer bleeding
1. Introduction
Peptic ulcer disease (PUD) is defined as the mucosal break of the upper gastro-
intestinal tract due to acid peptic digestion resulting in ulcer formation which
extends beyond the muscularis mucosae into the submucosa. Most commonly it
occurs in the stomach and first part of the duodenum but can also occur in the distal
esophagus, distal duodenum, and jejunum and in the Meckel’s diverticulum with
heterotrophic gastric mucosa [1]. The size of the ulcer varies from 5 mm to several
centimeters. On the other hand, erosions are superficial, less than 5 mm in size, and
limited to the mucosa. PUD is still one of the commonest disorders we encounter in
our clinical practice. The term “peptic” comes from the hormone pepsin which
plays an important role in causing mucosal break. Peptic ulcer (PU) bleeding is the
most common cause of upper gastrointestinal bleeding in the western world [2] and
results in significant morbidity, mortality, and healthcare costs [3]. PUD is a benign
condition, is easily treatable by medical therapy, and rarely requires surgery.
2. Epidemiology
PUD affects about 4.5 million persons per year in the United States (US) and
causes huge healthcare cost of about $3.3. billion/year [4]. The prevalence of PUD
varies with the prevalence of Helicobacter pylori (H. pylori) infection. In the United
States, the seroprevalence of H. pylori infection varies with age: 16.7% in young age
(20–29 years) group and 56.9% in older age (>70 years) group. It is also different
among different ethnicities: non-Hispanic whites 26.2%, non-Hispanic blacks
52.7%, and Mexican Americans 61.6% [5]. In developing countries, the prevalence
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of infection can be as high as 90% [6]. Systematic review of the literature from
developed countries estimated that the global incidence and prevalence of
physician-diagnosed PUD were 0.10–0.19% and 0.12–1.50%, respectively. But the
incidence and prevalence of PUD have decreased with the universal use of acid
suppressant therapy and decrease in prevalence of Helicobacter pylori infection due
to improved socioeconomic status and eradication of H. pylori infection after detec-
tion [7].
3. Etiopathogenesis
H. pylori infection and nonsteroidal anti-inflammatory drugs (NSAIDs) account
for majority of the cases of PUD. More than 90% of duodenal ulcers and >70% of
gastric ulcers are H. pylori positive [8]. A prospective study from Turkey found that
H. pylori infection alone was responsible for PUD in 75% of cases, both H. pylori
infection and NSAIDs in 50% of cases and NSAIDs alone in 10% of cases [9]. A
Japanese study showed that the long-term use of low-dose aspirin could cause PUD
in 6.2% of cases. The risk is increased in diabetic patients and in patients taking
anticoagulants [9]. Both NSAIDs and aspirin inhibit the cyclooxygenase pathway
and decrease the production of prostaglandin which is responsible for
cytoprotection of gastric mucosa by stimulating mucus and bicarbonate secretion
and increasing mucosal blood flow [10]. The chance of developing NSAID-induced
PUD increases in the presence of certain risk factors which include age more than
65, heart disease, past history of PUD, and co-administration of corticosteroid,
antiplatelets, and anticoagulants [11]. All NSAIDs can cause gastrointestinal injuries
which include inflammation, erosions, ulcerations, and bleeding. The relative risk
varies: the highest risk is associated with piroxicam and ketorolac; high risk with
indomethacin and naproxen; intermediate risk with meloxicam, diclofenac, and
ketoprofen; and low risk with ibuprofen and celecoxib [12]. About 11% of the US
population take NSAIDs on a regular basis. 15–30% of them have PUD on endos-
copy although clinical upper gastrointestinal events can occur in 1.5–4.5% of
patients taking NSAIDs [13].
H. pylori virulence factors are important in the pathogenesis of PUD. Cytotoxin-
associated gene A (Cag A), vacuolating cytotoxin A (Vac A), and induced by
contact with epithelium antigen (ice A) are associated with PUD. After entering the
stomach, H. pylori utilizes its urease enzyme to neutralize the gastric acidity.
H. pylori then moves toward the gastric epithelium where it binds to the gastric
epithelial cell receptors by its adhesion molecule [14]. Cag A is a strong immuno-
genic protein and measures the virulence of H. pylori infection. Cag A gene
increases production of IL-8 and activates nuclear factor-kB [15], and ice A
increases mucosal IL-8 expression. Gastric epithelial layer then activates its innate
immunity and neutrophils leading to gastritis and peptic ulcer formation. Vac A
toxin is a pore-forming toxin, and it not only stimulates vacuole formation in gastric
epithelial cells, parietal cells, T cells, and other immune cells but also helps H. pylori
in colonizing the stomach [16].
How H. pylori can cause duodenal ulcer while residing in the gastric mucus layer?
In H. pylori gastritis, the cytokine tumor necrosis factor inhibits somatostatin cells
(D cells) in the antral mucosa. As a result, gastrin secretion becomes uninhibited,
leading to hypergastrinemia, hyperacidity, and duodenal ulcer formation [17].
Another study suggests that gastric metaplasia and H. pylori colonization in the
duodenal bulb could play a critically important role in the pathogenesis of duodenal
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ulcer [18]. The gastric metaplasia becomes inflamed by H. pylori infection which
disrupts mucosal regeneration leading to duodenal ulcer formation [19].
There are certain unusual causes of PUD which we come across now and then in
our clinical practice.
Gastrinoma or Zollinger-Ellison syndrome may present as multiple gastric and
duodenal ulcers and accounts for 0.1% or more cases of PUD [20]. Other hormone
(histamine)-mediated PUD include systemic mastocytosis, polycythemia vera, and
basophilia in myeloproliferative diseases [21].
Besides NSAIDs and low-dose aspirin, few other medications can cause PUD.
These include clopidogrel (in combination with NSAIDs), corticosteroids (in
combination with NSAIDs), bisphosphonates, potassium chloride, spironolactone,
sirolimus, mycophenolate mofetil, hepatic artery infusion of 5-fluorouracil, and
selective serotonin reuptake inhibitors [22].
PUD can be due to another helicobacter infection called Helicobacter heilmannii
[23]. Gastrointestinal ulcerations due to cytomegalovirus, herpes simplex virus,
gastric and duodenal tuberculosis, and syphilis can mimic PUD.
Certain infiltrative diseases like Crohn’s disease and sarcoidosis can present like
PUD [24].
Family history is an independent risk factor for the development of PUD [25].
Blood group O individuals have higher susceptibility of getting H. pylori infection
[26] and are 35–40% more prone to develop duodenal ulcer than people with other
blood groups [27]. Salivary secretory status of A, B, and H antigens was also found
to be significant. Nonsecretor phenotypes of ABH antigens are more susceptible
to develop H. pylori infection and duodenal ulcer [28]. Genetic influence on the
formation of PUD is modest, and it is independent of the genetic susceptibility of
acquiring H. pylori infection [29]. Other risk factors for the development of PUD
include smoking and psychological stress [30].
When we think about the pathogenesis of PUD, we must consider two factors:
1.Mucosal protective factors: gastric mucus layer, prostaglandin, bicarbonate,
and mucosal blood flow.
2.Mucosal damaging factors: gastric acidity, pepsin, H. pylori infection, and
NSAIDs.
PU occurs when there is an imbalance between these factors.
3.1 Clinical features
Patients with PUDmay be symptomatic or asymptomatic. Symptomatic patients
generally present with dyspepsia, i.e., upper abdominal pain or discomfort. Most of
the time, the pain is felt in the epigastric region, but sometimes it can be in the right
upper quadrant or left upper quadrant of the abdomen. The pain is burning,
gnawing, or dull aching in nature and generally non-radiating but rarely can radiate
to the back in the case of posterior penetrating ulcer. Patients with gastric ulcer may
feel pain shortly after taking food, but in the case of duodenal ulcer, pain is gener-
ally felt 2–3 h after taking meal, or sometimes patients wake up at night with
epigastric pain. Duodenal ulcer pain is generally relieved after taking antacids or
food which has minimal effect on relieving gastric ulcer pain [31]. Sometimes
patients may feel gas and bloating sensation in the abdomen and sometimes may
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experience nausea and vomiting. About 30% of elderly patients with PUD may
remain asymptomatic [32]. This is also common in patients taking NSAIDs. Silent
PU generally presents with gastrointestinal bleeding [33].
Physical examination can be entirely normal except epigastric tenderness.
3.2 Diagnosis and evaluation
A thorough history and physical examination is necessary to evaluate the
patient. In each case, we should look for alarm features which include [34]:
1. Evidence of overt or occult gastrointestinal bleeding: hematemesis, melena,
anemia, heme-positive stool
2. Iron deficiency anemia
3.Dysphagia
4.Left supraclavicular lymphadenopathy (Virchow’s nodes)
5. Palpable abdominal mass
6.Symptom of impending perforation: severe persistent epigastric pain
7. Symptom of obstruction: persistent vomiting
8.Malignancy: anorexia, unintended weight loss
9.Age: >55 years
Diagnostic tests should include complete blood count, esophagogastroduo-
denoscopy (EGD), or upper gastrointestinal (UGI) series and tests for detection
H. pylori infection. EGD is preferred over UGI series as it has much higher diagnos-
tic yield and mucosal biopsy can be taken. Endoscopic views of clean-based duode-
nal ulcer and gastric ulcer are shown in Figures 1 and 2. During endoscopy, the
location, size, depth, and any sign or stigmata of bleeding can be evaluated, and
gastric biopsy from antrum, body, and incisura can be taken to detect H. pylori
infection [35]. Although endoscopic evaluation is the gold standard of diagnosis of
PUD, it is not cost-effective to perform EGD in all suspected cases of PUD. The
Figure 1.
Duodenal ulcer.
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alternative non-endoscopic strategies can be considered in the absence of alarm
features:
1.H. pylori test and treat: In a population where the prevalence of H. pylori
infection exceeds 20%, patients should get tested for H. pylori infection and, if
positive, should be treated by anti-H. pylori therapy [36, 37]. If H. pylori test is
negative or patients still remain symptomatic after anti-H. pylori therapy, they
should be given a 4–6 week course of proton pump inhibitor (PPI) therapy. If
PPI therapy fails, patients should be reassured, diagnosis should be reassessed,
and EGD should be considered. If patients respond to anti-H. pylori treatment
or PPI therapy, they can be managed without further investigation [38].
Stool for H. pylori antigen and urea breath tests are most accurate not only for
identification of active H. pylori infection but also for confirmation of eradication of
infection. Serology for H. pylori antibody is less reliable and cannot be used for
confirmation of cure.
2. Empiric acid suppression therapy: In a population where the prevalence of
H. pylori infection is 10% or less, empiric PPI therapy is most cost-effective. In
case of PPI failure, test-and-treat strategy should be applied as mentioned
above [39].
Physicians should make decision between test-and-treat strategy and empiric PPI
therapy for 4–6 weeks in the absence of alarm features. EGD should be considered
in the presence of alarm features. The American College of Gastroenterology (ACG)
and Canadian Association of Gastroenterology (CAG) suggest that patients
≥60 years of age presenting with dyspepsia should undergo upper endoscopy to
exclude any organic cause [40].
4. Management
4.1 Uncomplicated PUD
Risk factors for the development of PUD should be evaluated. Patients should be
advised to avoid NSAID intake, stop smoking, and limit drinking of alcohol. If the
patient is H. pylori positive, it should be treated, and eradication of infection should
be confirmed ≥4 weeks after completion of therapy [37]. There are different
Figure 2.
Gastric ulcers.
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regimens of anti-H. pylori therapy available. Patients’ previous history of antibiotic
exposure and prevalence of regional antibiotic resistance should be taken into
consideration. Treatment of H. pylori infection is summarized in Table 1 [41].
Antibiotics, histamine 2 receptor antagonists (H2RA), PPI, sucralfate, and bismuth-
containing medications (Pepto-Bismol) can interfere with the results of urea breath
test and stool for H. pylori antigen test and may give a false-negative result. Patients
should stop taking these medications at least 2 weeks prior to these tests [42, 43].
But patients can continue taking antacids (except Maalox total relief) as they do not
affect the accuracy of the tests.
Bismuth quadruple therapy or concomitant therapy can be considered as the
first-line therapy against H. pylori infection. PAC therapy should be considered as
Regimen Drugs Duration Eradication rate
(%)
PAC therapy PPI standard dose BID plus amoxicillin 1 g BID plus
clarithromycin 500 mg BID
14 days 70–85
PAM therapy PPI standard dose BID plus amoxicillin 1 g BID plus
metronidazole 500 mg TID
14 days 70–85
Bismuth
quadruple
therapy
PPI standard dose BID plus bismuth subcitrate (120–
300 mg) or subsalicylate (300 mg) QID plus
tetracycline 500 mg QID plus metronidazole 250 MG
QID
10–14 days 75–90
Concomitant
therapy
PPI standard dose BID plus amoxicillin 1 g BID plus
clarithromycin 500 mg BID plus metronidazole or
tinidazole 500 mg BID
10–14 days 94.4
Sequential
therapy
PPI standard dose plus amoxicillin 1 g BID for 5 days
followed by PPI plus clarithromycin 500 mg plus
either metronidazole or tinidazole 500 mg BID for
additional 5 days
Total
10 days
84.4
Hybrid
therapy
PPI standard dose plus amoxicillin 1 g BID for 7 days
followed by PPI standard dose plus amoxicillin 1 g
plus clarithromycin 500 mg plus metronidazole
500 mg BID for additional 7 days
Total
14 days
93.4
Levofloxacin
triple therapy
PPI standard dose and amoxicillin 1 g BID plus
levofloxacin 500 mg QD
10–14 days 83.1
Levofloxacin
sequential
therapy
PPI standard dose plus amoxicillin 1 g BID for 5–
7 days followed by PPI standard dose plus
amoxicillin 1 g plus metronidazole 500 mg BID and
levofloxacin 500 mg QD for additional 5–7 days
Total
10–14 days
92.2
LOAD therapy PPI (double dose) plus levofloxacin 250 mg plus
doxycycline 100 mg QD and nitazoxanide 500 mg
BID
7–10 days 88.9
Novel
concomitant
therapy
PPI standard dose and amoxicillin 1 g TID (if allergic
to penicillin, bismuth subcitrate 240 mg QID) plus
rifabutin 150 mg and ciprofloxacin 500 mg BID
10 days Regimen with
amoxicillin 95.2
Regimen with
bismuth
subcitrate 94.2
BID, twice a day; QID, four times a day; QD, once a day.
Table 1.
Treatment of H. pylori infection.
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first-line treatment in patients without history of exposure to macrolide and living
in an area where H. pylori clarithromycin resistance is low. If the first-line therapy
fails, susceptibility testing should be done if available, and susceptibility-based
therapy should be given. If susceptibility testing is not available, salvage therapy
should not contain the antibiotics used before. For example, if bismuth quadruple
therapy fails, clarithromycin- or levofloxacin-based therapy should be used as sal-
vage therapy. If clarithromycin-based therapy fails, bismuth quadruple therapy or
levofloxacin-based therapy should be used as salvage therapy. First-line therapy
generally fails in 25% of cases as a result of non-compliance, antibiotic resistance,
prior exposure to antibiotic, smoking, and younger age [44–46].
Acid suppressant therapy and mucosal cytoprotective agents are the main modes
of therapy for the healing of PU. Acid suppressant therapy includes H2RAs and PPIs
which are listed in Tables 2 and 3.
Duration of H2RA therapy: 90% of duodenal ulcers are healed by H2RA in
6–8 weeks, whereas 90% of gastric ulcers are healed by H2RA in 12 weeks [48].
Duration of PPI therapy: in the case of H. pylori-associated peptic ulcers, 90%
of the ulcers are healed by a 2-week course of PPI plus antibiotics for eradication
of H. pylori infection. This regimen followed by additional 2 weeks of PPI does
not make much difference in healing of peptic ulcer. PPI therapy should be
H2RA Dose Side effects
Cimetidine 800 mg qhs  4–8 weeks Gynecomastia, impotence, polymyositis, interstitial
nephritis, confusion, agitation, vitamin B12 deficiency
Ranitidine 150 mg BID  4–8 weeks Diarrhea, constipation, xerostomia, xeroderma
Vitamin B12 deficiency
Famotidine 40 mg qhs  4–8 weeks Agranulocytosis, angioedema, anaphylaxis, seizure
Nizatidine 300 mg qhs  4–8 weeks Nausea, vomiting, dyspepsia, insomnia, somnolence,
vitamin B12 deficiency
qhs, every night at bed time.
Table 2.
H2RA with dose and side effects.
PPI Dose Side effects
Omeprazole 20–40 mg qd  4–8 weeks Acute: headache, diarrhea
Esomeprazole 20–40 mg qd  4–8 weeks Chronic: hypocalcemia, hypomagnesemia, iron
deficiency, vitamin B12 deficiency, Clostridium
difficile infection, pneumonia, acute interstitial
nephritis, risk of fracture, drug-induced lupus
erythematosus [47]
Lansoprazole 15–30 mg qd  4–8 weeks
Dexlansoprazole 30–60 mg qd  4–8 weeks
Pantoprazole 20–40 mg qd  4–8 weeks
Rabeprazole 20 mg qd  4–8 weeks
qd, daily.
Table 3.
PPI with dose and side effects.
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continued for 8 weeks in case of gastric ulcer and 4 weeks in case of duodenal
ulcer [49].
In the case of NSAID-induced PUD, NSAIDs should be withdrawn if possible,
but PPIs are the drugs of choice. PPIs should be continued for at least 8 weeks for
the healing of PU. But maintenance dose of PPI should be continued to prevent
ulcer complications if the patient needs to be on NSAID or aspirin for other medical
conditions.
5. Mucosal cytoprotective agents
Misoprostol and sucralfate are mucosal cytoprotective agents.
Misoprostol is a synthetic analogue of prostaglandin E which is trophic to gas-
troduodenal mucosa, stimulates mucus and bicarbonate secretion from the gastro-
duodenal mucosa, and can form hydrophobic surfactant-like phospholipids in the
gastric epithelial cells [50]. Misoprostol can also inhibit gastric acid secretion by
suppressing histamine-stimulated cyclic AMP production but does not induce
hypergastrinemia [51]. Misoprostol can heal both gastric and duodenal ulcers.
Misoprostol 200 microgram four times a day should be given for 12 weeks. It can
prevent mucosal damage and formation of ulcers from the deleterious effects of
low-dose aspirin, NSAIDs, smoking, and alcohol [52]. Misoprostol is approved in
the United States for the prevention of NSAID-induced PUD. As misoprostol can
accelerate intestinal transit time and increase intestinal water and electrolyte secre-
tion, abdominal cramps and mild to moderate diarrhea can happen in up to 30% of
cases. Diarrhea can be reduced by taking food with misoprostol. Misoprostol can
also cause nausea, vomiting, menstrual cramps, and vaginal bleeding (due to uter-
ine contraction). Misoprostol is contraindicated in pregnant patients.
Sucralfate is the aluminum salt of sulfated sucrose. It coats the gastroduodenal
mucosa (both ulcerated and non-ulcerated areas); binds acid and pepsin; stimulates
the secretion of bicarbonate, prostaglandin, and epidermal growth factor; and thus
helps in healing of PU. Sucralfate is as good as H2RA in healing PU (duodenal ulcer
60–90% at 4–6 weeks and gastric ulcer 90% at 12 weeks) and has a lower rate of
recurrence of duodenal ulcer after healing as compared to H2RA [53, 54]. In the
United States, sucralfate is approved for the treatment of active duodenal ulcer not
related to NSAID. Side effects of sucralfate include nausea, vomiting, gastric upset,
itching, and skin rash. Less than 5% of sucralfate is absorbed from the gastrointes-
tinal tract into the systemic circulation and eliminated primarily in the urine.
Sucralfate should be avoided in patients with chronic kidney disease as it contains
aluminum.
6. Role of follow-up endoscopy
In the case of gastric ulcer, follow-up endoscopy is recommended 12 weeks after
medical therapy to evaluate for underlying malignancy. Surveillance endoscopy
should be individualized:
1. Surveillance endoscopy is necessary in patients with giant ulcer (>2 cm) and
malignant-looking ulcer (thick mucosal folds, irregular ulcer edges, mass
lesion) on index endoscopy; ulcer biopsy was not done on initial endoscopy;
initial endoscopy was done for upper gastrointestinal bleeding and unknown
etiology of the ulcer; patient remains symptomatic even after taking medical
therapy; index endoscopy showed gastric atrophy, intestinal metaplasia,
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dysplasia, or adenoma; and patient has risk factors for gastric cancer which
includeH. pylori positivity, age > 50 years, family history of gastric cancer, and
coming from a high prevalent area of gastric cancer (South Korea, Mongolia,
Japan, China, Bhutan, Kyrgyzstan, Chile, etc.). If the gastric ulcer seems to be
active or healing on surveillance endoscopy, four-quadrant biopsies from the
edges and base of the ulcer should be taken [55].
2. Surveillance endoscopy may not be necessary if the patient does not have any
risk factor for malignancy and the gastric ulcer is small, benign appearing, and
antral in location due to NSAID and the initial biopsy does not show any
dysplasia or malignancy [56].
In case of duodenal ulcer, surveillance endoscopy is generally not required
because of low risk of malignancy. But if the patient remains symptomatic or
symptoms recur despite medical therapy, surveillance endoscopy should be consid-
ered to evaluate for refractory ulcer or non-peptic nature of the ulcer which
includes Crohn’s disease, lymphoma, or tuberculosis.
7. Refractory and recurrent ulcers
When the ulcer does not heal up after a 12-week course of PPI therapy, it is
called refractory ulcer. 5–10% ulcers are refractory ulcers. When the ulcer recurs
after complete healing of the ulcer, it is called recurrent ulcer. 5–30% ulcers are
recurrent ulcers. The two most important causes of refractory and recurrent ulcers
are continued NSAID use and persistent H. pylori infection [57]. Other important
factors include cigarette smoking, smoking of crack cocaine, concurrent use of
corticosteroid, cytotoxic drugs (sirolimus, mycophenolate mofetil), alendronate,
methamphetamine, idiopathic hypersecretory duodenal ulcer, antral G-cell hyper-
plasia, gastrinoma, Crohn’s disease, sarcoidosis, cancer, non-H. pylori infection
(Helicobacter heilmannii), and infiltrative condition like gastrointestinal stromal
tumor and Kaposi sarcoma.
Patients with refractory or recurrent ulcers should be thoroughly investigated to
find out the causative factors which should be addressed. Twice daily PPI therapy
should be given for another 12 weeks. Then upper endoscopy should be done to
document complete healing of the ulcer. Patients with gastric ulcer should be
referred for surgery if ulcer does not heal by 24 weeks.
8. Complications
Common complications of PUD include bleeding, perforation, penetration, and
gastric outlet obstruction.
8.1 Bleeding
About 50% of all cases of upper gastrointestinal bleeding are caused by PUD
[58]. Patients may present with hematemesis, melena, anemia, or heme-positive
stool. At presentation, the patient’s hemodynamic status (pulse, blood pressure)
should be checked and resuscitative measures should be started. Patients should be
given intravenous crystalloid fluid to maintain blood pressure, and parenteral PPI
(esomeprazole or pantoprazole) should be started (continuous infusion or twice
daily intravenously). PPI therapy increases intragastric pH with stabilization of
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blood clot and reduces the risk of rebleeding and the need for surgery but does not
decrease overall mortality [59]. Blood transfusion should be given to keep the
hemoglobin ≥7 gm/dl, but in patients with hypovolemia or comorbidities like coro-
nary artery disease, hemoglobin target should be higher. Risk assessment should be
done to categorize high-risk or low-risk patients, level of care, need for blood
transfusion, timing of endoscopy, and timing of discharge. The Glasgow-Blatchford
bleeding score (GBS) is a useful screening tool (Table 4) to determine the need for
intervention [60]. Patients with a score of 0 are considered as low risk with mini-
mum risk of needing interventions like blood transfusion, endoscopy, and surgery,
and they should be considered for early discharge from the hospital. But all other
values (>0) fall into the category of high risk in terms of need for blood transfusion,
endoscopy, and surgery. A score of 6 or more has >50% risk of needing interven-
tion.
After resuscitation and stabilization, EGD should be done for diagnostic and
therapeutic purposes. During endoscopy, Forrest classification should be used to
assess the need for endoscopic intervention [61]. The different Forrest classes with
their prevalence and risk of rebleeding are mentioned in Table 5 [62]. Patients with
Forrest classes Ia, Ib, IIa, and IIb are considered to be high-risk candidates, and
endoscopic treatment should be provided to reduce the risk of rebleeding. Patients
with Forrest classes IIc and III do not require any endoscopic intervention. In fact,
Admission risk marker Score component value
Blood urea (mmol/L)
6.5–8.0 2
8.0–10.0 3
10.0–25 4
>25 6
Hemoglobin (g/dL) for men
12.0–12.9 1
10.0–11.9 3
<10.0 6
Hemoglobin (g/dL) for women
10.0–11.9 1
<10.0 6
Systolic blood pressure (mm Hg)
100–109 1
90–99 2
<90 3
Other markers
Pulse ≥100 (per min) 1
Presentation with melena 1
Presentation with syncope 2
Hepatic disease 2
Cardiac failure 2
Table 4.
GBS.
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patients with Forrest class III can resume a regular diet and can be discharged home
as long as they are hemodynamically stable, with stable hemoglobin and without
other comorbidities, and they have somebody at home to watch them [63].
Endoscopic treatment options can categorized into three main types:
1. Injection therapy: it is the oldest endoscopic hemostatic method. Epinephrine
(1:10,000 dilution) 0.2–2 ml aliquots are injected in four quadrants of the
bleeding stigmata. Initial hemostasis is obtained by its tamponade effect as well
as vasoconstrictive effect. But as it is less effective as a monotherapy, other
modalities of endoscopic treatment are added for better hemostasis [64].
2.Thermal therapy: it includes contact methods by bipolar or monopolar
cauterization and noncontact method by argon plasma coagulation (APC).
Contact methods work by coaptive coagulation. Bipolar cauterization is most
commonly used nowadays. A combination of epinephrine injection and bipolar
cauterization is more effective than either modality alone in achieving
hemostasis [65]. The APC machine has a high-frequency monopolar
electrosurgical generator, argon gas chamber, gas flowmeter, grounding pad,
flexible APC delivery catheter, and foot switch to activate gas and energy.
Argon gas release with delivery of electric current is synchronized by the foot
switch. The APC probe should be within 2–8 mm from the site of the targeted
tissue to induce plasma coagulation. The depth of the burn can be preset
between 0.5 and 3 mm. APC is an effective method of hemostasis in bleeding
peptic ulcer [66]. But APC can cause superficial ulcerations which are
generally healed up in 2–3 weeks.
3.Mechanical therapy: endoclips are widely used to stop bleeding from peptic
ulcer. There are different clips available which include resolution clip,
endoscopic hemoclip, Quick Clip2 (rotatable clip), Duraclip, and SureClip. All
these clips can go through the standard 2.8 mm endoscope channel and can
stop bleeding by grasping the bleeding vessel, reducing the chance of
rebleeding and need for surgery. Endoclips have been found to be superior to
injection therapy but comparable to thermocoagulation in bleeding PU [67].
They do not cause any tissue trauma, and as a result, ulcer healing is not
impaired. They are also MRI compatible. Disadvantages of endoclipping
include the following: (a) sometimes technical difficulty to clip the lesions in
locations like the posterior duodenal bulb, posterior gastric body, and proximal
lesser curve of the stomach, (b) limitation of use in large blood vessel (>2 mm
Forrest
class
Endoscopic finding Prevalence
(%)
Risk of recurrent bleeding on
medical management (%)
Ia Spurting arterial bleed 10 90
Ib Oozing of blood without visible
vessel
10 10–20
IIa Non-bleeding visible vessel 25 50
IIb Adherent blood clot 10 25–30
IIc Flat pigmented spot 10 7–10
III Clean-based ulcer 35 3–5
Table 5.
Forrest classes with prevalence and risk of recurrent bleeding.
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in diameter), (c) difficulty to grasp fibrotic tissue, and (d) requirement of
multiple clips [68].
Another clip called Ovesco clip is an over-the-scope clip used to stop peptic ulcer
bleeding. The bleeding area is suctioned into a cup attached to the scope, and then
the clip is deployed like band ligation.
A combination of at least two modalities of endoscopic treatment (injection,
thermal, or mechanical) is now the standard of care in the treatment of peptic ulcer
bleeding.
9. Endoscopic Doppler ultrasound
An ultrasound probe is passed through the endoscope channel and placed
directly onto the area of bleeding. An audible sound is heard if there is blood flow.
Arterial or venous blood flow can be detected. It is useful after endoscopic treat-
ment to evaluate the presence of any residual blood flow which can increase the
potential for rebleeding. It is also useful in Forrest IIc and III ulcers to find out any
vascular signal. Doppler ultrasound-guided endoscopic hemostasis reduces 30-day
rebleeding rate significantly and is also cost-effective [69].
Hemospray or hemostatic nanopowder is an alternative approach to obtain hemo-
stasis. The powder is delivered through a catheter which passes through the endo-
scope channel, and the powder is then sprayed over the bleeding site. The powder
forms a stable mechanical barrier at the site of bleeding. Initial success rate in
obtaining hemostasis is 75–100%, but rebleeding rate is 10–49% [70]. So hemospray
should be used as a bridge therapy in massive peptic ulcer bleeding when standard
endoscopic treatment fails.
Endoscopic therapy can control acute peptic ulcer bleeding with high success.
Primary hemostasis can be obtained in more than 90% of cases, but rebleeding can
occur in up to 15% of cases after therapeutic endoscopic procedure [71].
10. Role of second-look endoscopy
Second-look endoscopy is not routinely recommended after initial endoscopy
for the management of PU bleeding unless the endoscopist is concerned that
suboptimal treatment was given in the first endoscopy or there was poor visualiza-
tion due to blood or food debris during the first endoscopy [72].
11. Complications of endoscopic treatment
Complications could be due to sedation, patients’ comorbidities, and endoscopy
itself. Sedation-related complications include hypoventilation, hypoxia, aspiration
pneumonia, airway obstruction, arrhythmia, pulmonary embolism, myocardial
infarction, phlebitis, and vasovagal attack [73]. The complications of endoscopic
hemostasis include exacerbation of bleeding and perforation, but the overall inci-
dence is <0.5%. The rate of perforation after contact thermal therapy could be as
high as 2%. Following thermal therapy, induction or exacerbation of bleeding can
occur in up to 5% of cases [74].
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12. Failure of endoscopic therapy
If the endoscopic therapy fails to achieve hemostasis, the next step will be
angiography with transarterial embolization (TAE). Different agents are used for
embolization, and these include Gelfoam, endocoils, cyanoacrylic glues, and poly-
vinyl alcohol. The success rate of TAE in obtaining hemostasis is 52–98%, but
recurrent bleeding can occur in 10–20%, requiring repeat TAE [75].
13. Role of surgery
Surgery is indicated if TAE fails to stop PU bleeding. Emergency surgery
involves plication or oversewing of the ulcer with ligation of the bleeding artery
and truncal vagotomy and pyloroplasty. Wong et al. compared surgery vs. TAE
in bleeding PU patients who had failed endoscopic therapy. Surgery was
associated with less recurrent bleeding but more complications when compared
with TAE. There was no significant difference in the mean length of hospital
stay, need for blood transfusion, and 30-day mortality between the two groups [76].
In practice, the surgical intervention continues to diminish, but the radiological
intervention continues to increase in acute PU bleeding patients who have
unsuccessful endoscopic therapy. Surgery is also recommended for (a)
patients with perforation, (b) shock due to recurrent bleeding, (c) patients with
hemodynamic instability despite adequate resuscitative measures needing more
than three units of blood transfusion, and (d) unavailability of interventional
radiology.
14. Prognosis of bleeding peptic ulcer
The outcome depends on successful endoscopic hemostasis without recurrent
bleeding. The risk factors for recurrent bleeding include patients with renal failure
on dialysis; elderly patients on NSAID, antiplatelet agents, and anticoagulants;
patients with ulcer located on the posterior duodenal wall and lesser curve of the
stomach; and patients with active bleeding ulcer during endoscopy. Despite the
tremendous advances in technology, the mortality of acute PU bleeding remains
about 10% [77].
15. Perforation
In patients with PUD, the lifetime prevalence of perforation is 5%. Patients
generally present with acute abdomen. The triad of sudden onset of abdominal
pain, tachycardia, and abdominal rigidity is highly suggestive of PU perforation.
Smoking, NSAIDs, corticosteroids, old age, H. pylori infection, stress, and previous
history of PUD are risk factors for perforation [78]. Upright chest X-ray is generally
diagnostic, but it can miss free air under the diaphragm in 15% of cases. CT (com-
puterized tomography) is very sensitive in detecting the presence and site of perfo-
ration [79]. CT with oral contrast may also show leak. Exploratory laparotomy with
omental patch is the treatment of choice. PU perforation carries increased risk of
morbidity and mortality if not treated early.
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16. Penetration
When the ulcer crater erodes through the gastric wall or intestinal wall into the
surrounding structure but there is no free perforation or leakage of luminal contents
into the peritoneal cavity, it is called penetration [80]. The pancreas is the
commonest site of penetration. Other sites of penetration include the omentum,
biliary tract, liver, colon, mesocolon, and blood vessels. Patients may notice change
in pattern of abdominal pain, i.e., pain not being relieved by taking food or medi-
cation. Diagnosis is confirmed by CT with contrast which may show loss of fascial
plane between the gastric wall or intestinal wall and the surrounding structure,
band of soft tissue density between them, ulcer crater, sinus tract, and enlargement
of head of the pancreas in case of penetration into the pancreas [81]. Treatment is
surgical intervention.
17. Gastric outlet obstruction (GOO)
It occurs in less than 5% cases of PUD. Duodenal ulcer and pyloric channel ulcer
are generally associated with GOO. Pathophysiologically, reversible causes like
inflammation, edema, spasm, and pyloric dysmotility and irreversible cause like
fibrosis may lead to GOO. Patients present with nausea, vomiting, early satiety,
epigastric pain, and weight loss. Patients may develop severe dehydration, azote-
mia, hyponatremia, and hypochloremic and hypokalemic metabolic alkalosis with
paradoxical aciduria due to prolonged vomiting. First, the fluid and electrolyte
deficit should be corrected. Gastric contents should be removed by large-bore
Ewald tube, and then intermittent nasogastric tube suction should be continued for
a few days. Many cases of GOO due to PUD have reversible components which may
respond to this conservative treatment. Patients not responding to the conservative
treatment need endoscopic dilation or surgery [82, 83].
18. Conclusion
PUD is a common clinical problem. The two most important risk factors are
H. pylori infection and NSAIDs. Patients may present with dyspepsia or may
remain asymptomatic. Endoscopy is the gold standard for the diagnosis of PUD.
But as it is not possible to endoscope so many dyspeptic patients, there are some
non-endoscopic approaches depending on the prevalence of H. pylori infection in
the population. But ACG and CAG recommend EGD to be done in patients
≥60 years of age presenting with dyspepsia irrespective of alarm features.
Bismuth quadruple therapy or concomitant therapy should be considered as the
first-line therapy against H. pylori infection. In patients with PUD, eradication of
H. pylori infection (if positive) should be confirmed ≥4 weeks after completion of
therapy. PPI, H2RA, misoprostol, and sucralfate are the main agents used for
healing of PU. Surveillance endoscopy is recommended in certain gastric ulcers.
PUD can be complicated by bleeding, perforation, penetration, and gastric outlet
obstruction. Patients with bleeding peptic ulcer should be evaluated, resuscitated,
and started on intravenous/infusion of PPI. Diagnostic and therapeutic endoscopy
should be done to achieve endoscopic hemostasis. If endoscopic therapy fails, the
next step will be TAE or surgery. The mortality for peptic ulcer bleeding still
remains high.
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